Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Common Stock
ADXN | US
6.40
USD-0.25
-3.76%
ADXN | US
About Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
6.40
Open
6.63
High
6.63
Low
6.40
Addex Therapeutics Ltd a development-stage biopharmaceutical company discovers develops and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain anxiety and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie""Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva Switzerland."
View LessADXN | US
Risk
31.6
Sharpe
-0.27
Luna's Score
37/100
Recommendation
Sell
Luna says (ADXN | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
40.6%1 month
31.6%3 months
74.2%6 months
74.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.77
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-0.76
Ent. to rev.
7.12
PEG
-
Other Fundamentals
EBITDA
-11.07M
MarketCap
6.84M
MarketCap(USD)
6.84M
Div. yield
-
Op. margin
-780.14
Erngs. growth
-
Rev. growth
-81.80
Ret. on equity
-126.29
Short ratio
0.27
Short perc.
1.15
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.60
Range1M
1.38
Range3M
2.19
Volumes: Market Activity
Rel. volume
0.38
Price X volume
6.12K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.76 | - | Cheaper |
| Ent. to Revenue | 7.12 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.77 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 74.23 | - | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 6.84M | - | Emerging |
